Induction of apoptosis and cell cycle arrest on U266 multiple myeloma cell line by prochlorperazine

Download

index.pdf

Date

2016

Author

Hüsnügil, Hepşen Hazal

Metadata

Show full item record

Item Usage Stats

246
views

88
downloads

Multiple myeloma (MM) is a plasma cell neoplasm accounting for 1% of all malignancies and 13% of hematological malignancies. Despite the introduction of potent anticancer agents, MM remains as an incurable disease. High frequency of relapses and acquisition of resistance to current chemotherapy create a need for the development of novel agents for MM treatment. Prochlorperazine (PCP) is an FDA-approved phenothiazine drug, mainly used for the treatment of chemotherapy-associated nausea and vomiting. In addition, PCP was studied as a potent antitumor agent on various cancers such as melanoma, glioblastoma, colon and breast cancers. The aim of this study was to investigate the anticancer effect and mechanism of PCP on U266 MM cell line. We first studied the anticancer potential of PCP on U266 cell line at various doses and time points. Next, three flow cytometric apoptosis assays; JC-1, Caspase 3 and PE Annexin V-7 AAD were performed. PCP’s effect on cell cycle was examined with propidium iodide staining. As a part of the study, anticancer potential of cisplatin-PCP combination was also investigated. vi PCP exhibited dose- and time-dependent inhibitory effect on U266 cell viability. IC50 of PCP was calculated as 21.8 ± 0.8 µM. It was demonstrated that PCP exerted cytotoxic action through inducing apoptosis. No change in mitochondrial membrane potential was observed with JC-1 MMP assay which suggested activation of extrinsic apoptotic pathways by PCP. Cell cycle analysis indicated that exposure of U266 cells to PCP resulted in cell cycle arrest at G2/M phase. It was also demonstrated that PCP-cisplatin combination exhibited additive effect. These results indicated that PCP has potent anticancer activity alone and in combination with cisplatin on U266 MM cells. Further in-depth mechanistic studies and in vivo experiments are warranted to evaluate its therapeutic potential

Subject Keywords

Multiple myeloma., Trifluoperazine., Drug resistance., Apoptosis.

URI

http://etd.lib.metu.edu.tr/upload/12620245/index.pdf
https://hdl.handle.net/11511/25867

Collections

Graduate School of Natural and Applied Sciences, Thesis

Suggestions

OpenMETU
Core

Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line Durusu, Ipek Z.; Husnugil, Hazal H.; ATAŞ, Heval; BİBER, Aysenur; GEREKCİ, Selin; Gulec, Ezgi A.; Özen, Can (2017-04-01) Multiple Myeloma (MM) is a malignant neoplasm of bone marrow plasma B cells with high morbidity. Clofazimine (CLF) is an FDA-approved leprostatic, anti-tuberculosis, and anti-inflammatory drug that was previously shown to have growth suppression effect on various cancer types such as hepatocellular, lung, cervix, esophageal, colon, and breast cancer as well as melanoma, neuroblastoma, and leukemia. The objective of this study was to evaluate the anticancer effect and mechanism of CLF on U266 MM cell line. C...
Repurposing of antipsychotic agent trifluoperazine for multiple myeloma treatment: in vitro studies Ataş, Heval; Özen, Can; Erdoğ, Aslı; Department of Biotechnology (2016) Multiple Myeloma (MM) is a hematological malignancy resulting from the proliferation of plasma B cells in the bone marrow. MM accounts for 20 % of deaths from blood cancers and 2 % of deaths from all cancers. Although there have been remarkable developments in the treatment of MM, it is still an incurable disease due to the drug resistance problem. Therefore, development of novel therapies is especially important for MM patients. Drug repurposing is one of the promising strategies to discover new anticancer...
An update on molecular biology and drug resistance mechanisms of multiple myeloma Mutlu, Pelin; Gündüz, Ufuk (Elsevier BV, 2015-12) Multiple myeloma (MM), a neoplasm of plasma cells, is the second most common hematological malignancy. Incidance rates increase after age 40. MM is most commonly seen in men and African-American population. There are several factors to this, such as obesity, environmental factors, family history, genetic factors and monoclonal gammopathies of undetermined significance (MGUS) that have been implicated as potentially etiologic. Development of MM involves a series of complex molecular events, including chromos...
Anticancer activity of chlorpromazine on U266 multiple myeloma cell line Güleç, Aliye Ezgi; Özen, Can; Özçubukçu, Salih; Department of Biochemistry (2017) Multiple Myeloma (MM) is the second most common hematological malignancy caused by malignant growth of plasma B cells. It accounts for 10% of deaths from blood cancers. Although introduction of new drugs has significantly increased the success of chemotherapy, MM remains as an incurable disease with a high relapse rate. Drug repositioning, finding new uses for approved drugs, is a frequently used strategy for the discovery of new chemotherapeutic agents. Since already approved drugs are used, the cost and t...
Anti-Cancer Effects of Clofazimine As a Single Agent and in Combination with Cisplatin in Multiple Myeloma Durusu, Ipek; Hüsnügil, Hepşen Hazal; Atas, Heval; Biber, Aysenur; Gerekci, Selin; Gulec, Aliye Ezgi; Özen, Can (2016-12-02) Multiple Myeloma (MM) is a malignant neoplasm of bone marrow plasma B cells with high morbidity. Clofazimine (CLF) is an FDA-approved leprostatic, anti-tuberculosis, and anti-inflammatory drug that was previously shown to have growth suppression effect on various cancer types such as hepatocellular, lung, cervix, esophageal, colon, and breast cancer as well as melanoma, neuroblastoma, and leukemia. The objective of this study was to evaluate the anticancer effect and mechanism of CLF on U266 MM cell line. C...

Citation Formats

H. H. Hüsnügil, “Induction of apoptosis and cell cycle arrest on U266 multiple myeloma cell line by prochlorperazine,” M.S. - Master of Science, Middle East Technical University, 2016.